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Introduction
Cells can reach speci! c target tissues through the general circu-
lation by different mechanisms. Homing has been studied exten-
sively both in vitro and in vivo with different cell types, such as 
leukocytes or hematopoietic stem cells (Butcher, 1991; Fu and 
Liesveld, 2000); it is believed to rely on adhesion molecules and 
cytokines receptors by a multistep cascade, consisting of a roll-
ing process followed by ! rm adhesion and transmigration into 
the surrounding tissue (Peled et al., 1999; Grabovsky et al., 
2000). The repertoire and the level of cytokine expression by the 
target tissue, as well as expression of the relative receptors on 
endothelium, in" uence the ef! ciency of homing. For example, 
stromal-derived factor (SDF) 1 favors the arrest of progenitors 
on vascular endothelium, whereas interleukin (IL) 8 promotes 
stem cell mobilization from the marrow (Laterveer et al., 1996; 
Peled et al., 1999). Although these mechanisms have been eluci-
dated to a large extent for leukocytes and hematopoietic stem cells, 
far less is known for other types of stem cells. Mesoangioblasts 
were recently characterized as a population of vessel-associated 
stem cells that differentiate into several mesoderm cell types, 
including skeletal muscle (Minasi et al., 2002). They have been 
shown to restore to a signi! cant extent muscle structure and 
function in a mouse model of muscular dystrophy (Sampaolesi 
et al., 2003). One main reason for the partial effect of mesoan-
gioblasts in this model is likely to be ascribed to the limited 
ability of these cells to reach and colonize the muscle, depending 
in turn on incomplete adhesion and extravasation.
Mesoangioblast extravasation must be directed by selec-
tive mesoangioblast–endothelial cell recognition. Microarray 
analysis revealed that mesoangioblasts express E-selectin, β7 
integrin, AlCAM, several cytokines receptors, and CD44 but 
lack many of the leukocyte molecules implicated in transmigra-
tion (Taglia! co et al., 2004). To increase the ef! ciency of mus-
cle repair by mesoangioblasts, it would be essential to increase 
their migration to skeletal muscle, with the additional bene! t of 
reducing unspeci! c trapping in the capillary ! lters of the body, 
such as liver and lung. Here, we report that expression of α4 
 integrin and exposure of cells to SDF-1 or TNF-α improve up to 
! vefold migration of wild-type (WT) mesoangioblasts to the 
dystrophic muscles and consequent production of new ! bers 
that express the normal copy of the mutated gene. These results 
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 Effi cient delivery of cells to target tissues is a major problem in cell therapy. We report that enhancing delivery of mesoangioblasts leads to a complete 
 reconstitution of downstream skeletal muscles in a mouse 
model of severe muscular dystrophy (α-sarcoglycan ko). 
Mesoangioblasts, vessel-associated stem cells, were 
 exposed to several cytokines, among which stromal-
derived factor (SDF) 1 or tumor necrosis factor (TNF) α 
were the most potent in enhancing transmigration in vitro 
and  migration into dystrophic muscle in vivo. Transient 
 expression of α4 integrins or L-selectin also increased sev-
eral fold migration both in vitro and in vivo. Therefore, 
combined pretreatment with SDF-1 or TNF-α and expres-
sion of α4 integrin leads to massive colonization (>50%) 
followed by reconstitution of >80% of α-sarcoglycan–
 expressing fi bers, with a fi vefold increase in effi ciency 
in comparison with control cells. This study defi nes the 
 requirements for effi cient engraftment of mesoangioblasts 
and offers a new potent tool to optimize future cell therapy 
protocols for muscular dystrophies.
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Abbreviations used in this paper: ctx, cardiotoxin; HMGB, high mobility group 
box; ICAM, intercellular adhesion molecule; IL, interleukin; mdx, X chromosome–
linked muscular dystrophy; MMP, metalloproteinase; PECAM, platelet endothelial 
cell adhesion molecule; SDF, stromal-derived factor; SG, sarcoglycan; VCAM, 
vascular cell adhesion molecule; WT, wild-type.
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elucidate the migration mechanism of mesoangioblasts and 
open a therapeutic opportunity for improving ef! cacy of cell 
therapy in muscular dystrophy.
Results
Differentiated myotubes and SDF-1 
or TNF-훂 cytokines induce mesoangioblast 
transmigration in vitro
Mesoangioblasts (clone D16; Sampaolesi et al., 2003) were 
starved for 12 h in the absence of serum and then subjected to 
transmigration assays using transwell chambers, as described 
previously (Mohle et al., 1997). In a ! rst series of experiments, 
we created an arti! cial environment where mesoangioblasts 
would face an activated endothelial layer separating them from 
differentiating muscle cells (much as it happens in regenerating 
muscle) or speci! c cytokines with known chemoattractive 
 potency. As shown in Fig. 1 A (left), mesoangioblasts were unable 
to cross endothelium-coated ! lters in the absence of stimuli. 
However, multinucleated myotubes but not undifferentiated 
myoblasts induced active migration of mesoangioblasts but not 
primary ! broblasts. This effect was slightly stronger than that 
induced by FGF, used as a positive control. Fig. 1 A (right) 
shows a representative ! eld of the lower side of the ! lter, ! xed 
and stained.
We also performed the transmigration assay through 
 endothelium-coated ! lters in the presence of a panel of cyto-
kines for which mesoangioblasts have receptors (Taglia! co 
et al., 2004). The presence of SDF-1 and TNF-α in the lower 
chamber caused a tenfold increase of mesoangioblast migra-
tion, a signi! cantly more robust effect than that elicited by FGF 
or high  mobility group box (HMGB) 1, previously described 
as an enhancer of mesoangioblast migration (Palumbo et al., 
2004); IL-1 had little effect, whereas IL-6 and -10 had no effect 
(Fig. 1 B, left). Mesoangioblasts stained at the lower side of the 
! lter, con! rming the positive transmigration effect of SDF-1 
and TNF-α (Fig. 1 B, right).
This is in accordance with the fact that myotubes secrete 
these cytokines at a higher rate than myoblasts. As shown in Fig. 
1 C, SDF-1 or TNF-α as well as IL-6 and monocyte chemotactic 
protein 1 were detected at a higher level in the supernatant from 
myotubes than in the corresponding supernatant from  myoblasts. 
Figure 1. Induction of mesoangioblast trans-
migration in vitro by cytokines. (A) Mouse 
 mesoangioblasts or fi broblasts were plated 
on endothelium-coated transwell fi lters and 
 induced to migrate for 6 h in the presence 
of C2C12 or L6 myoblasts or differentiated 
 myotubes. FGF was used as positive migration 
control. A representative out of fi ve indepen-
dent experiments run in duplicate is shown 
(left). Transmigrated mesoangioblasts were 
fi xed, stained, and counted, and a representa-
tive image of different conditions is shown 
(right). *, α < 0.01. (B) Mesoangioblasts or 
fi broblasts were plated on endothelium-coated 
transwell fi lters and induced to migrate for 6 h 
the in presence of different cytokines. One rep-
resentative out of fi ve independent experiments 
run in duplicate is shown (left). A representa-
tive image of the transmigrated mesoangio-
blasts under the different conditions is also 
shown (right). *, α < 0.005; **, α < 0.01. 
(C) Supernatants from fi broblast, myoblast, or 
myotube cultures were collected after 4 d, and 
different cytokines were detected using the 
mouse multicytokine-detection system. One out 
of two experiments is shown.
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These data suggest that differentiated myotubes may secrete 
growth factors or cytokines such as SDF-1 or TNF-α that favor 
mesoangioblast transmigration by either a chemotactic effect 
and/or by modifying the endothelium barrier.
Mesoangioblast migration in vivo
To assess the ability of mesoangioblasts to migrate in vivo 
from the vessel lumen to muscle interstitial tissue (see Fig. 8), 
we injected 5 × 105 GFP-labeled mesoangioblasts into the 
right femoral artery of WT C57 (previously injected intramus-
cularly with cardiotoxin [ctx]), X chromosome–linked muscu-
lar dystrophy (mdx), and α-SG–null mice. Mice were killed 
6, 12, or 24 h after injection, the muscles (quadriceps, gastroc-
nemius, and tibialis) from treated (right) and contralateral legs 
as well as ! lter organs (liver, spleen, and lung) were collected, 
and RNA was extracted. The percentage of migrated meso-
angioblasts in each recipient organ was calculated by real-time 
PCR for GFP expression as a percentage of the value corre-
sponding to the total number of injected cells. As shown in 
Fig. 2 A, mesoangioblasts were able to migrate to the muscles 
of the treated legs; %10% of injected cells could be recovered, 
whereas most of injected cells were retained in the different 
! lter organs without reaching the contralateral muscles. 
We set our time of analysis at 6 h after injection for the in vivo 
experiments, as we observed that with the exception of ctx-
treated mice, the number of injected cells  remains constant for 
the ! rst 12 h after the injection and thereafter decreases to vary-
ing extents (up to 50% of the value observed at 6 h; Fig. 2 A) to 
increase again in the following days (see Fig. 9 A). Interestingly, 
mesoangioblasts migrate more ef! ciently to muscles of ctx-
treated normal mice or of α-SG–null mice (Fig. 2 A, top and 
bottom) than to muscles of the mdx mouse (Fig. 2 A,  middle). 
As shown in Fig. 2 B, the presence of a higher concentration 
of TNF-α (and to a minor extent SDF-1) in muscles from 
ctx-treated WT or α-SG–null mice than in mdx mice could 
explain the preferential migration of mesoangioblasts. 
 Although other cytokines were found to be more abundant 
in the muscles of mdx mice, these did not affect in vitro trans-
migration of mesoangioblasts (IL-1, -6, and -10) or, alterna-
tively, mesoangioblasts do not express the corresponding 
 receptors (monocyte chemotactic protein 1 and IL-8).
Mesoangioblast migration depends on age
Mesoangioblasts were injected in the femoral artery of WT 
(ctx injected), mdx, or α-SG–null mice at 2 or 8 mo of age, 
and different organs were collected after 6 h. As shown in 
Fig. 3 A, the number of mesoangioblasts that reached the 
damaged muscles was reduced to half when the injection was 
performed on old mice. This effect could be due to different 
adhesion molecules expressed by vessels in the muscles 
of young and old mice. Alexa 488–labeled mAbs anti–
MAdCAM-1 and anti–E- or anti–P-selectin were injected 
in the tail vein of α-SG–null mice, and after 20 min, their 
accumulation was studied with intravital video microscopy. 
As shown in Fig. 3 B, E- and P-selectin were barely detected 
in the muscles of old α-SG–null mice. In contrast, in young 
α-SG–null mice, E- and P- selectin were clearly detected on 
capillaries and small vessels in the muscles. MAdCAM-1 
and E- or P-selectin were not  detected in muscles from old 
mdx mice, whereas only MAdCAM-1 was slightly expressed 
in young mdx mice (unpublished data). mRNA expression 
analysis con! rmed that E- and P-selectins are highly ex-
pressed in muscles of 2-mo-old α-SG–null mice but barely 
detectable in 8-mo-old mice (Fig. 3 C). These results show 
that in addition to the reduction of the microvasculature that 
Figure 2. In vivo mesoangioblast migration. (A) Mesoangioblasts were 
injected into the right femoral artery (treated muscles) of 2-mo-old WT 
 (preinjected with ctx), mdx, or α-SG–null mice. After 6, 12, or 24 h, differ-
ent organs were collected and the number of migrated cells was calculated 
by real-time PCR for GFP. A mean of three independent experiments run in 
triplicate is shown. (B) Muscles from 2-mo-old WT (either control or prein-
jected with ctx), mdx, or α-SG–null mice were homogenized and analyzed 
for cytokine expression with the mouse multicytokine-detection system.
One out of two experiments is shown.
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accompanies fat and connective tissue accumu lation in  aging, 
dystrophic muscles, reduced expression of adhesion mole-
cules may further impair stem cell migration.
Mesoangioblasts migrate more effi ciently 
to injured muscles than other types 
of stem cells
Different types of stem cells have been shown to circulate and 
to be able to differentiate into skeletal muscle, thus representing 
potential candidates for a cell therapy protocol. Therefore, we 
compared migration to muscles of mesoangioblasts with mes-
enchymal and neural stem cells. 2.5 × 105 EGFP mesenchymal, 
neural, or mesoangioblast stem cells were injected into the fem-
oral artery of mdx or α-SG–null mice, and after 6 h, quadriceps, 
gastrocnemius, and tibialis from the treated leg and liver, spleen, 
and lung were collected, and the percentage of donor cells was 
calculated by real-time PCR for GFP. As shown in Fig. 4, meso-
angioblasts reached the muscles of the injected leg in higher 
numbers than the other stem cell populations in both animal 
models (left). These data show that mesoangioblasts naturally 
migrate to dystrophic muscle in comparison with the other cells 
tested. Interestingly, mesenchymal stem cells were recovered 
preferentially in the lungs (Fig. 4, right). Experiments with 
acutely isolated, noncultivated EGFP-hematopoietic stem cells 
were also performed. Even though results are not directly com-
parable with those obtained with in vitro–expanded cells, we 
observed that most hematopoietic cells were retained in the 
liver and the spleen (unpublished data).
Pretreatment of mesoangioblasts with 
SDF-1 or TNF-훂 increases their migration 
in vitro and in vivo
In an attempt to increase the number of mesoangioblasts that mi-
grate to skeletal muscles, we followed two approaches. First, we 
pretreated mesoangioblasts with the cytokines SDF-1 and TNF-α 
for 12 h before challenging them in the transwell assay. The re-
sults, shown in Fig. 5 A, clearly indicated that pretreatment with 
either SDF-1 and TNF-α stimulated mesoangioblast migration to 
the same extent observed when the same cytokines were present 
in the lower chamber. Therefore, SDF-1– or TNF-α–pretreated 
Figure 3. Mesoangioblast migration depends on age. (A) GFP mesoan-
gioblasts were injected into the right femoral artery (treated muscles) of 
2- or 8-mo-old WT (preinjected with ctx), mdx, or α-SG–null mice, and 
after 6 h, organs were collected and the percentage of migrated cells 
was calculated by real-time PCR for GFP. A mean of three independent 
experiments run in triplicate is shown. (B) Intravital microscopy of Alexa 
488 E- and P-selectin and MAdCAM-1 on the vascular endothelium 
from striated muscles were performed on α-SG–null mice of 2 and 8 mo. 
Isotype antibodies controls are also shown. A representative image out 
of three independent experiments is shown. (C) mRNA expression of 
P- and E-selectin in muscles taking from two α-SG–null mice of 2 or 8 mo 
analyzed by PCR.
Figure 4. Migration to dystrophic muscle of different types of stem cells. 
Mesoangioblasts, mesenchymal, or neural stem cells derived from homo-
EGFP mice were injected into the femoral artery of α-SG–null mice, and 
 after 6 h, treated muscles and fi lter organs were collected. Samples were 
subjected to real-time PCR for the presence of GFP. A mean of three inde-
pendent experiments run in triplicate is shown.
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GFP mesoangioblasts were injected through the femoral artery 
of ctx-pretreated WT, mdx, or α-SG–null mice, and after 6 h, 
muscles and ! lter organs were collected and analyzed by real-
time PCR for presence of GFP. As shown in Fig. 5 B, both SDF-1 
and TNF-α had a modest effect on WT mice (probably because 
of the acute in" ammation induced by ctx) but increased about 
Figure 5. SDF-1 and TNF-훂 favor mesoangio-
blast migration. (A) GFP mesoangioblasts 
 pretreated with different cytokines (without pre-
treatment for chemotaxis assays) were plated 
on endothelium-coated fi lters and induced to 
migrate for 6 h (in the presence of different cy-
tokines for chemotaxis assays). FGF was used 
as positive control. One representative out of 
fi ve independent experiments run in duplicate 
is shown. * α < 0.005; **, α < 0.01. (B) GFP 
mesoangioblasts pretreated with 50 ng/ml 
SDF-1 or TNF-α were injected into the femoral 
artery of 2-mo-old WT (preinjected with ctx), 
mdx, or α-SG–null mice, and after 6 h, muscles 
and fi lter organs were analyzed by real-
time PCR for the presence of migrated cells.
*, α < 0.01; **, α < 0.05. (C) SDF-1– or 
TNF-α–pretreated mice mesoangioblasts were 
analyzed by fl ow cytometry for the presence of 
different surface molecules. One representa-
tive out of two independent experiments is 
shown. Mean fl uorescence intensity is shown 
at the bottom right of each plot. (D) A gene ar-
ray containing oligos corresponding to differ-
ent mouse adhesion molecules was hybridized 
with cDNAs probes retrotranscribed from the 
RNA of mesoangioblasts pretreated with 
TNF-α or SDF-1. Relative RNA levels of selected 
mRNAs normalized to β-actin expression are 
shown. Data presented are the mean of two 
 independent experiments. (E) SDF-1– or TNF-α–
pretreated mesoangioblasts were incubated 
with MMP inhibitor GM1489 or with anti-
bodies against different surface molecules and 
induced to  migrate for 6 h through  endothelium-
coated  fi lters. A representative out of three 
 independent experiments run in duplicate is 
shown. *, α < 0.005; **, α < 0.01.
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twofold the migration of mesoangioblasts to the injured mus-
cles of dystrophic mice. Consistently, the number of mesoangio-
blasts detected in the ! lter organs was reduced to almost half 
of control.
We then attempted to identify the surface molecules that 
may be responsible for the changes observed in mesoangioblast 
migration after pretreatment with SDF-1 or TNF-α. The possi-
ble change in the expression of several candidate surface mole-
cules was ! rst investigated by FACS analysis (Fig. 5 C). Many 
of the tested molecules were not changed by treatment with ei-
ther SDF-1 or TNF-α. However, CD44 expression was increased 
more than twofold by TNF-α and not by SDF-1, whereas 
FGFR1 expression was increased only by SDF-1. Although 
these two molecules are involved in migration processes and 
could explain part of our effects, we performed a microarray 
analysis for 125 genes, including surface receptors, to look for 
more candidates genes induced in mesoangioblasts by SDF-1 or 
TNF-α. 16 genes were modi! ed after pretreatment of mesoangio-
blasts with either SDF-1 or TNF-α (Fig. 5 D). Caspase-8 
(Casp8), caveolin 1 (cav-1), CD44, cadherin 1 (Cdh1), metallo-
proteinase (MMP) 13, or vascular cell adhesion molecule 
(VCAM) 1 expression was increased two- to threefold only by 
TNF-α pretreatment, whereas Itgαv (αv integrin), MMP-14, or 
neural cell adhesion molecule (NCAM) 1 were induced approx-
imately twofold only by SDF-1 pretreatment. Pretreatment with 
either TNF-α or SDF-1 increased expression of intercellular 
 adhesion molecule (ICAM) 1, NCAM-2, different MMPs, 
platelet endothelial cell adhesion molecule (PECAM), and 
trombospondins. To verify the role in mesoangioblast transmi-
gration of those molecules that appeared to be more potently in-
duced by TNF-α or SDF-1, we repeated the transwell assay in 
presence of antibodies against VCAM-1, αv integrins, ICAM-1, 
or CD44 or MMP inhibitor GM1489. As shown in Fig. 5 E, 
 antibodies against CD44 partially inhibited transmigration 
 induced by TNF-α, whereas antibodies against αv integrin in-
hibited SDF-1–induced transmigration. Blocking MMP activity 
with GM1489 dramatically inhibited transmigration induced by 
both molecules. Together, these data suggest that TNF-α and 
SDF-1 increase mesoangioblast transmigration in vitro and 
 migration to muscles in vivo by increasing expression of several 
molecules, among which CD44 and MMP appeared the most 
relevant in the case of TNF-α and αv integrin and MMP 
 appeared most relevant in the case of SDF-1.
훂4 integrin and L-selectin are necessary 
for effi cient mesoangioblast migration 
in vitro and in vivo
As revealed by microarray analysis (Taglia! co et al., 2004), 
 mesoangioblasts do not express some of the key molecules 
that control rolling and extravasation of leukocytes and different 
stem cells such as L-selectin, α4 integrin, or β2 integrin 
(Butcher, 1991). Therefore, we transfected mesoangioblasts 
with vectors expressing these molecules and EGFP, which 
 allowed FACS selection of transfected cells. To verify the 
 expression of these proteins, a Western blot for total lysates of 
transfected mesoangioblasts were performed (Fig. 6 A, left). 
Figure 6. 훂4 integrin increases mesoangioblast migration. (A) Mesoangioblasts were transfected with expression vectors encoding different surface mole-
cules and EGFP and lysed with Laemmli buffer. Protein and GFP expression was checked by Western blot (left). Expression at the cell surface was also ana-
lyzed by fl ow cytometry (right). Mean fl uorescence intensity is also shown in each plot. Transfected or pretreated mesoangioblasts were subjected to skeletal 
muscle differentiation assays. The mean of three different experiments is shown (bottom). (B) Mesoangioblasts transfected with one, two, or all three vectors 
expressing the different surface molecules and EGFP were plated on endothelium-coated fi lters and induced to migrate for 6 h. A representative out of fi ve 
independent experiments run in duplicate is shown. *, α < 0.005. (C) Mesoangioblasts transfected with vectors expressing α4 integrin or L-selectin 
and GFP were injected into the right femoral artery of 2-mo-old α-SG–null mice, and after 6 h, muscles and fi lter organs were collected. Percentage of 
 migrated cells was calculated after performing real-time PCR for GFP. A mean of three independent experiments run in triplicate is shown. * α < 0.005; 
**, α < 0.01.
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Correct surface expression of these proteins was also veri! ed by 
" ow cytometry analysis (Fig. 6 A, right). Finally, mesoangio-
blasts transfected with the different constructs or pretreated 
with TNF-α or SDF-1 were subjected to differentiation assays. 
Expression of L-selectin or α4 integrin did not interfere with 
skeletal muscle differentiation of mesoangioblasts in vitro, 
whereas expression of β2 integrin inhibited differentiation 
(Fig. 6 A, bottom).
To assess whether the expression of these molecules could 
improve mesoangioblast migration, cells transfected with one, 
two, or all three constructs were subjected to transmigration in 
vitro assay through activated endothelium. As shown in Fig. 6 B, 
α4 (but nor β2) integrin or L-selectin expression increased 
 mesoangioblast transmigration six- to eightfold, whether or not 
C2C12-derived myotubes were present in the lower chamber. 
Thus, expression of the counterpart ligands for these molecules 
at the surface of the activated endothelium was suf! cient to al-
low mesoangioblast transmigration independent of the presence 
of myotubes, with a chemoattractant-independent mechanism. 
Cotransfection of two or all constructs had only a slightly cu-
mulative effect, which was not statistically signi! cant. When 
α4 integrin– or L-selectin–expressing mesoangioblasts were in-
jected into the femoral artery of ctx-treated WT, mdx, or α-SG–
null mice, the number of cells that reached downstream muscles 
was increased approximately twofold with some variability in 
different mice (Fig. 6 C). In general, α4 integrin appeared to be 
more ef! cient than L-selectin. Therefore, expression of α4 inte-
grins and L-selectin by mesoangioblasts improves their migra-
tion, possibly by favoring their interaction with the ligands 
expressed on the endothelium surface.
Pretreatment with TNF-훂 or SDF-1 
of 훂4 integrin–expressing mesoangioblasts 
increased their migration to muscles 
fi ve- to sixfold
We then tested the possibility of additive or synergistic effects 
of cytokines and adhesion molecules. Mesoangioblasts, previ-
ously transfected with α4 integrin or/and L-selectin constructs, 
were pretreated for 12 h with TNF-α or SDF-1 and then sub-
jected to transmigration assay through endothelium. As shown 
in Fig. 7 A, some combinations were able to improve mesoan-
gioblast transmigration in vitro, the most ef! cient of which was 
TNF-α treatment of α4 integrin–expressing cells, which mi-
grated in vitro 15-fold more ef! ciently than control. Therefore, 
these cells were injected into the femoral artery of the different 
animal models: results showed that almost 50% of injected cells 
reached the injured muscles after 6 h, with a concomitant reduc-
tion in the number mesoangioblasts detected in ! lter organs 
(Fig. 7 B). To follow these modi! ed mesoangioblasts, we per-
formed immunohistology analysis of the tibialis anterior from 
an α-SG–null mouse whose femoral artery had been previously 
(6 h) injected with control or modi! ed mesoangioblasts. 
As shown in Fig. 8 A (right), TNF-α–pretreated, α4 integrin–
transfected mesoangioblasts (GFP, right) were able to cross the 
endothelial barrier of vessels (stained with PECAM, right) and 
localized in the surrounding muscle tissue (green, left) outside 
of and sometimes underneath laminin (red, left) in a position 
typical of satellite cells. Untreated mesoangioblasts were less 
ef! cient in crossing the vessel wall, and many fewer were found 
around the muscle ! bers. To monitor the distribution of injected 
cells at 48 h after injection, muscle sections of transplanted 
mice were stained for GFP, laminin, and PECAM. As shown in 
Fig. 8 B, all GFP-modi! ed mesoangioblasts were localized in 
the muscle tissue, mainly outside of the basal lamina and far 
from vessels, but in some case underneath it, in a position typi-
cal of satellite cells. Indeed, as shown in Fig. 8 C, 2 wk after 
 injection, we detected GFP mesoangioblasts expressing the 
 satellite cell Myf-5 (Beauchamp et al., 2000; Fig. 8 C, left) that 
occupied the typical position of satellite cells (Fig. 8 C, right).
TNF-훂–pretreated, 훂4 integrin–expressing 
mesoangioblasts induce enhanced 
expression of 훂-SG
5 × 105 TNF-α–pretreated, α4 integrin–expressing mesoangio-
blasts were injected into the femoral artery of α-SG–null mice, 
and after 6 h or 1, 15, 30, 60, or 120 d, the tibialis anterior from 
treated legs was collected and analyzed by real-time-PCR for 
GFP or α-SG. As shown in Fig. 9 A, after an initial modest de-
cline, the number of both control and modi! ed mesoangioblasts 
began to increase by 15 d after the injection and reached a  plateau 
by 1 mo. At all time points, modi! ed mesoangioblasts were 
four- to sixfold more numerous than control mesoangioblasts. 
Figure 7. Combination of TNF-훂 and 훂4 integrin increases mesoangio-
blast homing. (A) TNF-α– or SDF-1–pretreated mesoangioblasts transfected 
with vectors expressing α4- and/or L-selectin and GFP were induced to 
 migrate for 6 h through endothelium-coated fi lters. A mean of three 
 independent experiments run in duplicate is shown. *, α < 0.005; 
**, α < 0.05. (B) TNF-α–pretreated mesoangioblasts transfected with vectors 
expressing α4 integrin–EGFP were injected through the femoral artery of 
WT (preinjected with ctx), mdx, or α-SG–null mice, and after 6 h, muscles 
and fi lter organs were collected and analyzed by real-time PCR for the 
presence of GFP. A mean of three independent experiments run in triplicate 
is shown. *, α < 0.01; **, α < 0.05.
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Likewise, α-SG became detectable %15 d after injection, when 
mesoangioblasts had been incorporated into regenerating ! bers 
and continued to increase thereafter, again at a much higher 
level in muscles injected with modi! ed mesoangioblasts. As a 
matter of fact, 4 mo after a single injection, the level of 
α-SG expression in the tibialis of injected α-SG–null mice was 
almost 60% of that detected in the corresponding tibialis from 
a WT mouse. At the same time, the level of expression of α-SG 
in the tibialis injected with control mesoangioblasts was only 
10% of a WT mouse. In agreement with RT-PCR data, α-SG 
was detected in almost all (>90%) the muscle ! bers of the tibi-
alis injected with treated mesoangioblasts, whereas a lower per-
centage (%20% with a weaker staining) of positive ! bers was 
present in the tibialis injected with control mesoangioblasts 
(Fig. 9 B). The newly synthesized α-SG protein was also ana-
lyzed by Western blot. As shown in Fig. 9 C, after 4 mo, the 
quantity of protein detected was approximately sixfold higher 
in muscles injected with treated mesoangioblasts than with 
control cells. To test whether increased expression of α-SG 
would correspond to increased motility, mice were subjected to 
a running test on a treadmill. The number of times that WT 
mice, α-SG–null mice, either untreated or treated with control 
or modi! ed (TNF-α–pretreated, α4 integrin–expressing) meso-
angioblasts, fell into the grid when running was recorded. 
Fig. 9 D shows that α-SG–null mice injected with modi! ed me-
soangioblasts fell into the grid less frequently than noninjected 
or control mesoangioblast–injected α-SG–null mice. After this 
exercise test, many of the null mice appeared to be extremely 
fatigued and took a relatively long time to recover from the 
 exercise, whereas treated mice seemed to recover from the 
 effort much faster. Together, these data show that mesoangio-
blasts pretreated with TNF-α and transfected with α4 integrins 
are not only able to more ef! ciently reach the damaged muscle 
but also to reconstitute SG-positive ! bers with much higher 
 ef! ciency and improved muscle function.
TNF-훂–pretreated, 훂4 integrin–expressing 
human mesoangioblasts reach damaged 
mdx-SCID muscles with higher effi ciency
To test whether a similar protocol would also be suitable for 
human cells, we isolated human mesoangioblasts from small 
vessels of biopsies from normal human adult muscle. These 
cells have morphology and gene expression similar to their 
mouse counterparts, a ! nite lifespan, and a similar ability to 
differentiate into different types of muscle cells, osteoblasts, 
and adipocytes. Human mesoangioblasts were serum starved 
and subjected to transmigration assays using transwell chambers. 
As shown in Fig. 10 A, human mesoangioblasts were also 
 unable to cross endothelium-coated ! lters in absence of stimuli. 
However, multinucleated myotubes or pretreatment of cells with 
TNF-α or SDF-1 increased human mesoangioblast  migration 
four- to eightfold without signi! cant enhancement of  human 
! broblast migration.
We then transfected human mesoangioblasts (that also do not 
express these molecules; unpublished data) with vectors express-
ing L-selectin, α4 integrin, or β2 integrin and, after transfection, 
Figure 8. Treated mesoangioblast cross-
 muscles vessels. (A) Muscles from α-SG–null mice 
killed 6 h after injection with TNF-α–pretreated 
mesoangioblasts transfected with α4 integrin–
EGFP vectors or with control mesoangioblasts 
were frozen. Sections were immunostained 
with anti-GFP, anti-PECAM, and/or anti-laminin 
antibodies as indicated. DAPI was used for 
 nuclear staining. Bar, 100 μm. (B) Muscles 
from α-SG–null mice killed 48 h after injection 
with treated mesoangioblasts were stained 
with anti-GFP (green), anti-laminin (red), and 
anti-PECAM (magenta) antibodies. Hoechst 
was used as nuclear staining. Bar, 100 μm. 
(C) Muscles from α-SG–null mice killed 2 wk 
after injection with treated mesoangioblasts 
were stained with anti-GFP (green), anti-myf5 
(red; left), anti-myosin (red; right), and/or anti-
laminin (magenta) antibodies. Hoechst was 
used as nuclear staining. Arrows indicate GFP-
positive cells located underneath the muscle 
fi ber basal lamina and expressing the satellite 
cell marker Myf5. Bars, 5 μm.
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selected the GFP-positive cells with FACS. To verify the correct 
surface expression of these proteins, transfected human meso angio-
blasts were also analyzed by " ow cytometry analysis (Fig. 10 B). 
Fig. 10 C shows that pretreatment of α4 integrin– or L-selectin–
expressing human mesoangioblasts with TNF-α or SDF-1 
increased their ability to cross the endothelial barrier in transwell 
assays by %18-fold. Therefore, human mesoangioblasts, pretreated 
with TNF-α and transfected with vectors encoding for α4 integrin 
or L-selectin were injected into the femoral artery of mdx-SCID 
mice that do not reject human cells. Fig. 10 D shows that almost 
40% of human modi! ed mesoangioblasts reached the muscles 6 h 
after intrafemoral artery injection, with a concomitant reduction in 
the number of cells detected in ! lter organs. Together, these data 
show that it is possible to increase human mesoangioblast migra-
tion to dystrophic muscle with an experimental protocol similar 
to that developed for mouse mesoangioblasts.
Discussion
Until now, intraarterial delivery of mesoangioblasts (Sampaolesi 
et al., 2003) has appeared to be the most promising cell therapy 
protocol for muscular dystrophy because of a partial but signi! -
cant restoration of muscle structure and function. However, 
 before clinical trials, many hurdles have yet to be solved, among 
them ef! cient delivery to target tissue. In this work, we provide 
a new experimental strategy, based on pretreatment with cytokines 
Figure 9. Treated mesoangioblasts improve 
훂-SG expression. (A) Muscles from α-SG–null 
mice injected with mesoangioblasts pretreated 
with TNF-α and transfected with the α4 integrin–
EGFP vector or with control mesoangioblasts 
were collected after different days and sub-
jected to real-time PCR for the presence of 
α-SG or GFP. A mean of two independent ex-
periments run in triplicate is shown. (B) Immuno-
staining of tibialis anterior from α-SG–null mice 
collected 30 or 120 d after injection with con-
trol mesoangioblasts or with mesoangioblasts 
pretreated with TNF-α and transfected with 
α4. Laminin is shown in red, and α-SG or GFP 
protein is shown in green. Bars: (left) 100 μm; 
(right) 20 μm. (C) Western blot for α-SG pro-
tein of lysates from tibialis from α-SG–null mice 
collected at different times after injection with 
control mesoangioblasts or with mesoangio-
blasts pretreated with TNF-α and transfected 
with α4 integrin. Myosin heavy chain (MyHC) 
is shown as protein level control. One repre-
sentative out of four independent experiments 
is shown. (D) α-SG–null mice injected or not 
with mesoangioblast control or pretreated with 
TNF-α and transfected with α4 integrin were 
exercised after 1 mo on a treadmill at 7 m/min. 
The number of times they fell onto the grid was 
recorded. C57 WT mice are presented as 
 control. Bars represent mean and standard 
 deviation of two independent tests (n = 4 mice 
for each group). *, α < 0.01; **, α < 0.005 
(α-SG vs. WT); γ (nontreated vs. treated meso-
angioblasts) = 0.01.
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and surface expression of certain adhesion molecules that 
 dramatically improves migration of mesoangioblasts to the 
 affected muscles.
Testing mesoangioblast migratory 
activity in vitro
We initially measured mesoangioblast migration with a tran-
swell assay, already proven as a reliable indicator of the mecha-
nisms that govern cellular traf! cking in vivo (Mohle et al., 
1997). Mesoangioblasts cross the endothelium and migrate to-
ward multinucleated myotubes, an in vitro setting mimicking 
the microenvironment encountered by these cells after intraarte-
rial injection, as myotubes roughly correspond to newly regen-
erated, immature ! bers that may produce factors. Microarray 
analysis has also shown that mesoangioblasts express several 
receptors for cytokines, of which CXCR-4 and TNF-R raise the 
possibility that these cells may respond to SDF-1 and TNF-α. 
Indeed, we found that SDF-1 and TNF-α were the most potent 
inducers of mesoangioblast migration, more than HMGB-1, 
which was previously reported to be an enhancer of mesoangio-
blast migration (Palumbo et al., 2004).
Mesoangioblasts migrate into skeletal 
muscles of young mice in vivo more 
effi ciently than in the muscles of old mice
Homing to skeletal muscle in vivo proceeds through multiple 
mechanisms, which are only partially mimicked by in vitro 
 assays. When WT mesoangioblasts were injected through the 
femoral artery of ctx-treated WT or dystrophic mice, only a 
small percentage (%10%) of injected cells reached downstream 
skeletal muscle, whereas most cells that had probably passed 
through the capillary network ended in the venous circulation 
and were trapped in ! lter organs. Indeed, a very low number of 
injected cells could be detected in the contralateral muscles. 
 Interestingly, the percentage of donor cells that could be recov-
ered from the muscles of α-SG–null or ctx-treated WT mice 
was higher than in mdx mice, possibly because of the different 
cytokine pattern expression in the muscles (Durbeej and Campbell, 
2002). Moreover, age turned to be a critical factor for the suc-
cess of cell transfer. Vessels present in the dystrophic muscle 
of young but not old mice expressed adhesion molecules neces-
sary for the correct extravasation. The progression of the dis-
ease is characterized by reduced regeneration of muscles ! bers, 
which are replaced by scar and fat. Microcirculation is also 
 altered, thus reducing the possible delivery of cells or viral 
 vectors. Our data show that, in addition, reduced expression of 
adhesion molecules further reduces migration of stem cells. 
This is an important issue, as it strongly suggests that cell 
 therapy protocols in older patients would have much-reduced 
chances of success in comparison with younger patients.
Mesoangioblasts migrate to skeletal 
muscle in vivo more effi ciently 
than other stem cells
Stem cells have the ability to migrate to their target tissue through 
different routes, including circulation. Neural stem cells are re-
cruited to areas of brain injury even when injected in the general 
circulation (Pluchino et al., 2003); hematopoietic stem cells nat-
urally home to bone marrow and other hematopoietic organs 
(Rosu-Myles et al., 2005); ! nally, mesenchymal stem cells can 
also circulate and engraft inside bone (Bensidhoum et al., 2004). 
We compared the natural ability of these different stem cells to 
colonize the damaged muscles of mdx or α-SG–null mice upon 
intraarterial injection. We found that mesoangioblasts are able to 
reach damaged muscles more ef! ciently than the other stem cells 
tested, including hematopoietic stem cells (although different 
 experimental conditions prevent a direct comparison), which 
 migrate preferentially to liver and spleen.
Figure 10. Pretreatment of human mesoan-
gioblasts improves migration to muscles. 
(A) Human mesoangioblasts or fi broblasts pre-
treated with different cytokines were plated on 
endothelium-coated fi lters and induced to mi-
grate for 6 h in presence of C2C12 myoblasts 
or differentiated myotubes. FGF was used as 
positive migration control. One representative 
out of three independent experiments run in 
duplicate is shown. *, α < 0.005. (B) Human 
mesoangioblasts were transfected with expres-
sion vectors encoding different surface mole-
cules and GFP, and their expression at the cell 
surface was analyzed by fl ow cytometry. 
Mean fl uorescence intensity is shown in each 
plot. (C) Human mesoangioblasts transfected 
with vectors expressing different surface mole-
cules and pretreated or not with different cyto-
kines were plated on endothelium-coated fi lters 
and induced to migrate for 6 h. One represen-
tative out of three independent experiments 
run in duplicate is shown. *, α < 0.005. 
(D) Human mesoangioblasts transfected with 
vectors expressing α4 integrin or L-selectin and 
GFP and pretreated with TNF-α were injected into the right femoral artery of 2-mo-old mdx-SCID mice, and after 6 h, muscles and fi lter organs were 
 collected. The percentage of migrated cells was calculated after performing real-time PCR for GFP with the different samples. A mean of three independent 
experiments run in triplicate is shown. *, α < 0.01.
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Enhancing mesoangioblast 
migratory activity
Previous work has shown that HMGB-1 stimulates proliferation 
and migration of mesoangioblasts to dystrophic muscles that 
expresses this molecule (Palumbo et al., 2004). We con! rm 
those data; however, in a screen for factors and cytokines for 
which mesoangioblasts are known to express receptors (Taglia! co 
et al., 2004), we observed that SDF-1 and TNF-α are more 
 potent as chemoattractants. Interestingly, our work shows that 
pretreatment of donor cells with these cytokines is suf! cient to 
activate or increase expression of certain surface proteins neces-
sary for the migration and extravasation process, immediately 
suggesting a simple ex vivo treatment of cells that does not re-
quire expression in target muscles. We further investigated the 
mechanisms involved in this migration increase through a low-
density array hybridization performed with mesoangioblasts 
pretreated with TNF-α or SDF-1. The role of the different genes 
modi! ed by the treatment was studied in the transmigration 
 assay using inhibitors or blocking antibodies. This experiment 
 revealed that TNF-α acts via an MMP- and CD44-dependent 
mechanism, whereas the effect of SDF-1 was mediated by 
MMPs and αv integrins.
Mesoangioblasts do not normally express many of the 
leukocytes molecules needed for an ef! cient rolling and arrest 
at blood vessels, which may explain why most of the injected 
cells do not bind ef! ciently, " ow through the muscle capillary 
net, and are ! nally trapped inside ! lter organs. Therefore, 
L-selectin, α4 integrin, and β2 integrin were expressed in me-
soangioblasts, forming dimers with other integrins (such as β1, 
β7 or αl, αm) already expressed by these cells. Expression of 
L-selectin and α4 integrin did not alter the myogenic differenti-
ation of mesoangioblasts, whereas expression of β2 integrin 
did, a fact that precludes future use in vivo. The expression of 
α4 integrin or L-selectin resulted in an eightfold increase of 
mesoangioblast transmigration in vitro and a twofold increase 
in the number of mesoangioblasts that reached the damaged 
muscles, simultaneously reducing their trapping in ! lter organs. 
The combined strategies (i.e., pretreatment with TNF-α of 
 mesoangioblasts expressing α4 integrin) resulted in a 15-fold 
 increase of transmigration through endothelium in vitro and 
more than ! vefold enhanced migration in vivo, with >50% 
of injected cells now present into the downstream muscles. 
 Immunohistology con! rmed these data, as many more modi! ed 
mesoangioblasts could be detected in muscle interstitium and, 
later, within muscle ! bers (as detected by expression of 
α-SG) or as satellite cells.
Increased migration corresponds 
to increased muscle repair and motility
Increasing migration to the target tissue has two positive out-
comes: (1) it delivers more cells to repair the target tissue and (2) 
it reduces the number of cells that are trapped in ! lter organs. 
This number is large, and in the case of lungs, it may cause respi-
ratory problems that are not evident in mice. In addition, human 
mesoangioblasts have a ! nite number of cell divisions, and this 
may in the end represent a limiting factor if most of them are 
wasted outside the target tissue. However, increased migration 
does not necessarily mean increased tissue repair. In principle, if 
more cells reach the target tissue, they may undergo a reduced 
number of divisions in vivo and thus give rise to a similar number 
of differentiated cells. Our data show that this is not the case.
We previously showed that mesoangioblasts are able to 
regenerate in part the damaged muscles after three injections 
and long periods (Sampaolesi et al., 2003). Other types of stem 
cells have also been shown to reconstitute the skeletal muscle of 
dystrophic mice to various extents (Corbel et al., 2003; De Bari 
et al., 2003), but a quantitative analysis was not reported. 
 Mesoangioblasts treated with TNF-α and expressing α4 integ-
rin were able to reach damaged muscles and to produce α-SG 30 d 
after injection with dramatically increased ef! ciency,  allowing 
treated α-SG–null mice to improve the performance of exercise. 
4 mo after a single injection of modi! ed mesoangioblasts, 
α-SG–null mice expressed almost 60% of the α-SG detected in a 
WT mouse. Immunostaining of α-SG showed a partial recovery 
after 30 d and >90% of well-structured ! bers expressing α-SG 
after 4 mo. This corresponded to a  signi! cant increase in the 
 ability to run on a treadmill, despite a unilateral treatment.
In the perspective of a cell therapy in patients, it is important 
to test whether a similar protocol will also work with human cells. 
Human mesoangioblasts have been recently isolated from frag-
ments of vessels inside biopsies of postnatal human skeletal 
 muscle. Regarding the use of these cells in the present study, 
it is important to state that they have a morphology and marker 
expression similar to their murine counterparts, a ! nite lifespan 
(at variance with their murine counterparts), and a similar ability to 
differentiate into different types of solid mesoderm (unpublished 
data). Human mesoangioblasts were also exposed to TNF-α, 
which in the case of human cells was more potent than SDF-1, and 
transfected with either α4 integrin or L-selectin and, under these 
conditions, reached skeletal muscles of mdx-SCID mice threefold 
more ef! ciently than their corresponding untreated cells. Although 
these data suggest that further work may still be required to opti-
mize human mesoangioblast migration to skeletal muscle, they 
clearly indicate that the basic migration mechanisms are similar in 
mouse and human mesoangioblasts and equally susceptible to 
 enhancement by similar cytokines and adhesion molecules.
In conclusion, our results suggest that pretreatment of 
 mesoangioblasts with TNF-α and the presence of α4 integrin 
are required for the ef! cient delivery of stem cells to injured 
muscles in the course of muscular dystrophy. Pretreatment of 
stem cells with cytokines is a simple procedure, and inclusion 
of a relatively small cDNA in a viral vector, designed for gene 
 correction, is also a feasible procedure in the context of autolo-
gous cell therapy with engineered stem cells. Together, these 
strategies represent a novel and simple method for improving the 
migration of stem cells to damaged tissue and could be tailored 
in the future to different types of stem cells in different cell ther-
apy protocols requiring migration to other target tissues such as 
the heart or the bone.
Materials and methods
Reagents
Anti-GFP antibody and anti-isotype control antibodies were purchased 
from Chemicon. Anti–α4, anti–αv, and anti–β2 integrins; anti–L-selectin; 
 o
n
 J
u
ly
 2
1
, 2
0
0
7
 
w
w
w
.jc
b
.o
rg
D
o
w
n
lo
a
d
e
d
 fro
m
 
JCB • VOLUME 174 • NUMBER 2 • 2006 242
anti-CD44; anti-FGFR1; anti–VCAM-1; and anti–ICAM-1 antibodies were 
obtained from Serotec. Anti–L-selectin mAb Mel-14 was obtained from 
American Type Culture Collection. Anti–E- and anti–P-selectin mAbs (RME-1 
and RMP-1) were obtained as previously described (Walter et al., 1997; 
Souza et al., 1999). Anti–MAdCAM-1 and anti-PECAM were provided by 
E. Butcher (Stanford University, Stanford, CA) and E. Dejana (FIRC Institute 
of Molecular Oncology, Milan, Italy). Anti–α-SG and anti-myf5 antibodies 
were purchased from NovoCastra.
Most reagents and some antibodies were purchased from Sigma-
 Aldrich, unless stated otherwise. All the cytokines used were obtained from 
PeproTech. GM1489, the MMP inhibitor, was obtained from Calbiochem. 
Alexa 488 and Alexa F 647 labeling kit were obtained from Invitrogen.
mdx and C57BL10 WT mice were purchased from Charles River Lab-
oratories, and homo-EGFP mice were provided by A. Nagy (Mount Sinai 
Hospital, Toronto, Canada; Hadjantonakis et al., 1998). α-SG–null mice 
were a gift from K. Campbell (University of Iowa, Iowa City, IA; Sampaolesi 
et al., 2003). All mice were handled following institutional guidelines.
Cell cultures
C2C12 mouse myoblasts or L6 rat myoblasts were cultured in Dulbecco’s 
minimal essential medium plus 20% FBS and induced to differentiate in 
Dulbecco’s minimal essential medium plus 2% FBS. D16 mice mesoangio-
blasts were isolated from the dorsal aorta of mouse embryos (embryonic 
day 9.5), cloned, and expanded as described previously (Minasi et al., 
2002). Mesoangioblasts transduced with a lentiviral vector encoding the 
GFP protein were used for some experiments. Murine microvascular endo-
thelial H5V cells (a gift form E. Dejana, FIRC Institute of Molecular Oncol-
ogy) and mouse embryonic fi broblasts 3T3 were grown in Dulbecco’s 
minimal essential medium plus 10% FBS and starved for 12 h before func-
tional experiments. Mesenchymal and hematopoietic stem cells were iso-
lated from homo-EGFP mice using the SpinSep TM kit (StemCell 
Technologies, Inc.) and checked for purity according to the manufacturer’s 
instructions. Neural stem cells were isolated from the forebrains of embryos 
(embryonic day 11.5) as previously described (Galli et al., 2000).
Constructs
Murine or human β2 integrin, L-selectin, and α4 integrin mRNA cloned in 
a pT7T3D-Pac1 vector were purchased from Research Genetics. Inserts 
were cloned into pIRES2-EGFP expression vector from CLONTECH Labora-
tories, Inc., and transfected into mice or human mesoangioblasts with Lipo-
fectamine (Invitrogen). GFP-positive mesoangioblasts were sorted and used 
for the different experiments.
Differentiation assays
Treated mesoangioblasts were cocultured with L6 cells in low serum (2%). 
After 3 d, dishes were fi xed with 4% PFA, and the number of mouse nuclei 
stained with DAPI inside myosin-positive cells was counted. The percentage 
of differentiation was calculated against the total number of cells.
Real-time PCR
Total RNA from different organs was isolated with TRIzol protocol  (Invitrogen) 
and reverse transcribed by Taqman kit (Platinum Taq DNA polymerase; 
Invitrogen). RT-PCR was performed for E- and P-selectin (E-selectin primers: 
Fw, C C A T G T T C C A C G T C A A G G A C C ; Rw, G C C A T G T G A T A G G C C A C A G ; 
and P-selectin primers: Fw, C C A G T A T C T A G A C C C G A A G G ; Rw, G C C A T T-
C T C T C T C C T C G A A A C A C ), and mRNA expression was analyzed by aga-
rose gel. Alternatively, real-time quantitative PCR was done on a real-time 
PCR system (Mx3000P; Stratagene). Each cDNA sample was amplifi ed 
in duplicate by using the SYBR Green Supermix (Bio-Rad Laboratories) for 
GFP or ε chromosome detection (GFP primers: Fw, A A G T T C A T C T G C A C C-
A C C G ; Rw, T C C T T G A A G A A G A T G G T G C G ; and ε chromosome primers: 
Fw, A A G C G A C C C A T G A A C G C A T T ; Rw, T T C G G G T A T T T C T C T C T G T C ) or 
the Taqman Universal PCR master mixture containing AmpliTaq Gold DNA 
with commercial primers (Applied Biosystems) for α-SG detection. Data 
are expressed as the percentage of migrated cells, which is calculated by 
comparing the concentration of target genes in our sample with the total 
input of injected cells. For the Taqman assay, the level of α-SG detected 
represents the specifi c signal detected in the sample (mesoangioblast-
injected α-SG–null mouse tibialis anterior) compared with a positive control 
(WT mouse tibialis anterior; i.e., 100% of positive fi bers).
In vitro transwell migration assay
8-μm transwell fi lters (Corning) were coated with 1% gelatin, and endothe-
lial cells H5V (previously preactivated by 12 h of exposure to TNF-α) were 
plated to confl uence on them for 24 h. Confl uence of the endothelial mono-
layer was assessed by measuring the diffusion of BSA from the upper to the 
lower chamber. At the same time, C2C12 were grown on a p24w plate 
with or without differentiated medium for 0–4 d. 104 mice mesoangio-
blasts, WT or pretreated or transfected, were plated in Dulbecco’s minimal 
essential medium containing 2% serum on the upper side of transwell 
chamber 24 h after plating H5V cells, and the chamber was then moved 
to the wells containing differentiated C2C12 or different cytokines. After 
6 h of transmigration, migrated mesoangioblasts on the lower side of the 
 fi lter were fi xed in 4% paraformaldehyde, stained with crystal violet, and 
counted using an inverted microscope (fi ve random fi elds of the lower face 
of the transwell membrane at 20× magnifi cation). The results show 
 migrated cells as a percentage of the total number of input cells.
In vivo migration assay
2- or 8-mo-old WT (injected slowly through all the anterior surface of the 
tibialis with a 27-gauge needle containing 100 μl of 5 μM ctx [Sigma-
 Aldrich] 12 h before treatment), mdx, or α-SG–null mice were injected 
through the right femoral artery with 5 × 105 mouse mesoangioblasts. 
After 6, 12, or 24 h, animals were killed, and different muscles (quadri-
ceps, gastrocnemius, and tibialis) or fi ltered organs (liver, lung, and spleen) 
were collected. RNA was extracted, and a real-time PCR for GFP was per-
formed in all the samples as described (see Real-time PCR). Data are repre-
sented as a percentage of migrated cells (percentage of GFP detected) to 
the different organs relative to the input value.
Intravital microscopy
50 μg of Alexa 488–labeled mAbs anti–E- or anti–P-selectin or anti–
 MAdCAM-1 were injected through the tail vein of α-SG–null mice. 20 min 
later, the animal was anesthetized and perfused through the left ventricle 
with cold PBS (Homeister et al., 1998). Blood vessels of striated muscles 
were visualized with a silicon-intensifi ed target video camera (VE-1000 
SIT; Dage-MTI) and monitor (SSM-125CE; Sony).
Microarray analysis
For mRNA analysis, total RNA was extracted from treated mesoangioblasts 
using TRIzol. cDNA was prepared by reverse-transcription reaction and 
 hybridized to the GEArray gene expression array MM-010 (SuperArray) 
for extracellular matrix and adhesion molecules according to the manufac-
turer’s instruction. Data were subjected to densitometric analysis using 
GEArray Expression Analysis Suite (SuperArray). RNA levels were 
 expressed as the relative density after normalizing the hybridization signal 
to β-actin.
Western blot
Mesoangioblasts were transfected with the different constructs (see 
Constructs) and lysed directly in Laemmli buffer on ice. Lysates were 
 resolved on 10% SDS-PAGE under reducing conditions, and proteins were 
transferred to nitrocellulose membrane (Hybond-ECL; GE Healthcare). 
Membranes were revealed with anti-GFP and anti–α4 or anti–β2 integrins 
or anti–L-selectin antibodies.
Flow cytometry
Mesoangioblasts pretreated with different cytokines or transfected with dis-
tinct constructs were detached with PBS plus 5 mM EDTA on ice and incu-
bated with antibodies against the different surface molecules for 30 min at 
4°C. Cells were then incubated with a Alexa 488–conjugated anti–mouse Ig. 
Finally, fl uorescent samples were analyzed in a FACSCalibur fl ow cytometer 
(Becton Dickinson).
Cytokines measurements
Supernatants from fi broblasts, myoblasts, or myotube cultures were col-
lected after 4 d of culture and analyzed with the Beadlyte mouse multicytokine-
detection system (Upstate) for measuring cytokines according to the 
manufacturer’s instructions. Muscles from different animal models were 
 homogenized and cytokines were measured using the same kit protocol.
Inmunohistology
Tibialis anterior muscles of α-SG–null mice were removed from mice previ-
ously injected with mesoangioblasts and frozen in liquid N2 cooled 
 isopentane. Serial muscle sections were fi xed with 4% PFA, permeabilized, 
satured, and immunostained as previously described (Sampaolesi et al., 
2003) with anti-GFP, anti–α-SG, anti-laminin, anti-myosin, anti-PECAM, or 
anti-myf5 antibodies. Alexa 488 or 594 or Cyane (Invitrogen) were used 
as secondary staining Ig and DAPI for nuclear staining. Isotype control 
 antibodies were used as negative staining. Images were taken with a 
 microscope (S100 TV; Carl Zeiss MicroImaging, Inc.).
 o
n
 J
u
ly
 2
1
, 2
0
0
7
 
w
w
w
.jc
b
.o
rg
D
o
w
n
lo
a
d
e
d
 fro
m
 
MESOANGIOBLAST MIGRATION • GALVEZ ET AL. 243
Treadmill test
α-SG–null mice (n = 4 for each of the four groups) injected or not with 
 control or treated mesoangioblasts were run on a treadmill (Columbus 
 Instruments) set at 7 m/min for 2 min before and after 1 mo from injection. 
WT C57 mice are also presented as healthy control. The back of the tread-
mill was equipped with a grid that discharged a mild current, a stimulus 
 designed to motivate the animal to keep running on the treadmill. Performance 
was measured by the number of times a mouse failed to stay on the running 
belt and fell into the stimulus grid. Running time was limited to 2 min 
 because the majority of the α-SG–null mice could not run any longer.
Statistical analysis
Statistical signifi cance of the differences between the percentage values 
was assessed by using the Kruskal-Wallis one-way analysis of variance by 
ranks test. α represents the signifi cance in each independent case.
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